Products
Online Inquiry
Tegatrabetan
Cat. No.:
OB0225WX-1720
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Tegatrabetan is a small-molecule antagonist of the Wnt/β-catenin pathway distinguished by its potential antineoplastic molecular properties.
Synonym:
BC2059; 1227637-23-1; Tegavivint; BC-2059; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; N-[(9E,10E)-3,6-bis[(3R,5S)-3,5-dimethylpiperidin-1-ylsulfonyl]-10-(hydroxyimino)anthracen-9-ylidene]hydroxylamine
CAS No.:
1227637-23-1
Compound CID:
46212391
Formula:
C28H36N4O6S2
Formula Weight:
588.74
Specification
Relative Density:
1.46 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Tegatrabetan is utilized in advanced oncological research as an antagonist of the beta-catenin/BCL9 interaction to study the inhibition of Wnt-driven transcription in hematologic malignancies.
Library Information
Target:
Wnt/β-Catenin
Receptor:
β-Catenin
Pathways:
Cytoskeletal signaling; Stem cells
Plate Number:
AOCL-23
Plate Location:
a5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
60 mg/mL; 101.91 mM
